Liver Transplant Failure Clinical Trial
Official title:
Retrospective Exploratory Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.
dd-cfDNA is a non-invasive method to measure graft function stability in liver transplant patients. Liver biopsy is the standard to determine liver rejection and graft function, but no tests exist currently to be able to help guide the IS regimen in these patients. LFTs are not as specific to determine graft function hence testing dd-cfDNA levels can help guide the Immunosuppression (IS )medications dosing and help identify rejection early. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04789213 -
Mortality, Morbidity and Risk Factors of Liver Retransplantation
|
||
| Completed |
NCT03858088 -
Early Allograft Failure Simplified Estimation (EASE) in Liver Transplantation
|
||
| Withdrawn |
NCT03846089 -
Retrograde Reperfusion Versus Antegrade Liver Transplant Reperfusion
|
||
| Active, not recruiting |
NCT03815864 -
Antibodies and Liver Retransplantation
|
||
| Recruiting |
NCT05361044 -
Liver Graft Viability Assessment During Normothermic Regional Perfusion
|
N/A | |
| Recruiting |
NCT05866796 -
Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation
|
||
| Active, not recruiting |
NCT03396016 -
Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation
|